Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 17/20 | 0.69 |
| ▸ | PGR | P06401 | 16/20 | 0.69 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.42 |
| ▸ | SHBG | P04278 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12949526 | 1.00 | AR (0.69) | ARPGRNR3C2MEN1CYP3A4 | |
| SCHEMBL12949519 | 0.87 | AR (0.67) | ARPGRNR3C2MEN1CYP3A4 | |
| SCHEMBL13062201 | 0.86 | AR (0.69) | ARPGRNR3C2MEN1CYP3A4 | |
| SCHEMBL12949520 | 0.86 | AR (0.69) | ARPGRNR3C2CYP3A4LMNA | |
| SCHEMBL12949545 | 0.86 | AR (0.69) | ARPGRNR3C2CYP3A4LMNA | |
| SCHEMBL12943047 | 0.83 | AR (0.76) | ARPGRNR3C2 | |
| SCHEMBL16572798 | 0.83 | AR (0.76) | ARPGRNR3C2 | |
| SCHEMBL12924043 | 0.82 | AR (1.00) | ARPGRNR3C2 | |
| SCHEMBL12923981 | 0.82 | AR (1.00) | ARPGRNR3C2 | |
| SCHEMBL12949523 | 0.81 | PGR (0.66) | ARPGRNR3C2MEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021472-A1 | 17-HYDROXY-19-NOR-21-CARBOXYLIC ACID-STEROID Y-LACTONE DERIVATIVE, USE THEREOF, AND MEDICAMENT CONTAINING THE DERIVATIVE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021472-A1 | 17-HYDROXY-19-NOR-21-CARBOXYLIC ACID-STEROID Y-LACTONE DERIVATIVE, USE THEREOF, AND MEDICAMENT CONTAINING THE DERIVATIVE | CYP17A1, NR5A1, CYP19A1 | AR 39/4885PGR 29/4885NR3C2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.